KRAS: Difference between revisions
(Created page with "KRAS is a gene that encodes a protein involved in cell signaling pathways that regulate cell growth, division, and survival. Mutations in the KRAS gene are among the most common genetic alterations in cancers, particularly in pancreatic, colorectal, and lung cancers. These mutations result in the continuous activation of the KRAS protein, leading to uncontrolled cell proliferation and tumor development. Identifying KRAS mutations in tumors is crucial for determining the...") |
No edit summary |
||
| Line 1: | Line 1: | ||
KRAS is a gene that encodes a protein involved in cell signaling pathways that regulate cell growth, division, and survival. Mutations in the KRAS gene are among the most common genetic alterations in cancers, particularly in pancreatic, colorectal, and lung cancers. These mutations result in the continuous activation of the KRAS protein, leading to uncontrolled cell proliferation and | KRAS is a gene that encodes a protein involved in cell signaling pathways that regulate cell growth, division, and survival. Mutations in the KRAS gene are among the most common genetic alterations in cancers, particularly in pancreatic, colorectal, and lung cancers. These mutations result in the continuous activation of the KRAS protein, leading to uncontrolled cell proliferation and tumour development. Identifying KRAS mutations in tumours is crucial for determining the most effective treatment strategies, as these mutations often indicate resistance to certain therapies, such as anti-EGFR monoclonal antibodies. By understanding the presence and role of KRAS mutations, clinicians can better tailor treatments to each patient's specific cancer profile, potentially improving outcomes and offering more personalized cancer care. | ||
Latest revision as of 14:24, 27 August 2024
KRAS is a gene that encodes a protein involved in cell signaling pathways that regulate cell growth, division, and survival. Mutations in the KRAS gene are among the most common genetic alterations in cancers, particularly in pancreatic, colorectal, and lung cancers. These mutations result in the continuous activation of the KRAS protein, leading to uncontrolled cell proliferation and tumour development. Identifying KRAS mutations in tumours is crucial for determining the most effective treatment strategies, as these mutations often indicate resistance to certain therapies, such as anti-EGFR monoclonal antibodies. By understanding the presence and role of KRAS mutations, clinicians can better tailor treatments to each patient's specific cancer profile, potentially improving outcomes and offering more personalized cancer care.
